These features can be initiated by the user to reduce the risk of hypoglycemia during periods of increased insulin sensitivity such as exercise (Ease-off) and to improve glucose outcomes when insulin sensitivity is lower such as during intercurrent illness, stress, or hormonal changes associated with the menstrual cycle or times of unusual hyperglycemia (Boost).11 There are currently no studies investigating the use of these features with ultra–rapid-acting insulins. Here, INS is linked to Hypoglycemia.